Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
Evidence suggests that blood-pressure lowering treatment provides consistent cardiovascular risk reduction across all chronic kidney disease stages, with a 5 mm Hg systolic reduction yielding similar hazard ratios in patients with and without CKD (0.91 vs 0.90). Worth noting that this relative benefit is notably attenuated in CKD patients with concomitant diabetes (HR 0.96 vs 0.88 without diabetes), indicating differential treatment responses in this high-risk subgroup.
British Heart Foundation.
Relevance: Meta-analysis examining cardiovascular risk management with antihypertensive therapy including ACE inhibitors relevant to formulary (enalapril). Though focused on adult CKD populations rather than pediatric cardiac diagnoses, provides evidence on blood pressure management strategies applicable to cardiovascular risk reduction in complex cardiac patients.